Company news

Zymeworks Inc. news in 2026

Zymeworks Inc.'s news releases, calls and decks from 2026, newest first.

View company

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

October 27, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 24, 2026

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

October 23, 2026

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

October 19, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

October 15, 2026

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

September 28, 2026

Zymeworks Completes Acquisition of Theravance Biopharma

September 23, 2026

Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

August 6, 2026

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 6, 2026

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

July 16, 2026

Zymeworks to Acquire Theravance Biopharma, Inc.

June 29, 2026

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

June 18, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

June 13, 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

May 14, 2026

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

April 20, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

April 16, 2026

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

April 15, 2026

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

April 8, 2026

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

March 31, 2026

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

March 29, 2026

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

March 17, 2026

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

March 16, 2026

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

March 2, 2026

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

March 2, 2026

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

March 1, 2026

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

February 12, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

January 27, 2026

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

January 12, 2026

Zymeworks Outlines Strategic Priorities and Outlook for 2026

January 11, 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

January 6, 2026

Calls in 2026

Decks in 2026